Quarterly report pursuant to Section 13 or 15(d)

5. Commitments and Contingencies (Details Narrative)

v2.4.0.8
5. Commitments and Contingencies (Details Narrative) (USD $)
In Thousands, unless otherwise specified
3 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Mar. 31, 2014
Potential severance under certain employment agreements $ 1,130    
Aggregated annual salaries under certain employment agreements 935    
Product revenue 2,795 2,721  
Vetericyn and Innovacyn
     
Product revenue 528 741  
More Pharma
     
Accounts receivable 722   790
Amortization of upfront fees (transaction costs) 375 375  
Transaction costs 16 16  
Innovacyn
     
Accounts receivable $ 299   $ 220